Pilot TMS in Mild TBI
Key facts
- Who runs it
- HealthPartners Institute
- Where
- Saint Paul, United StatesSee the site
- Trial code
- Status
- Active, not recruiting
- People taking part
- 20 people, planned
- Started
- 18 Jun 2025
- Expected to end
- Jul 2027
- Type of study
- Interventional
- Treatments tested
- Intermittent theta burst stimulation
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Clinical diagnosis of mTBI at least 4 weeks prior but not exceeding 12 months prior to the time of screening
- Age 18-65 years at the time of mTBI
- High burden of post concussive symptoms at time of screening, as measured by symptoms questionnaire (PCSS) ≥35*
Who cannot take part
- Inability to tolerate imaging; contraindication of imaging due to implants or metal
- Seizure disorder, active alcohol or substance use disorder
- Inability to speak and read English
- Anything else that, in the opinion of the PI/study physician, would place the subject at increased risk or preclude the subject's full compliance with or completion of the study
- Subject is pregnant or breast feeding
- Subject has participated in a clinical interventional trial in the last 3 months
Where in United States
- HealthPartners Neuroscience CenterSaint Paul, United States
About the trial
What the trial wants to find out
Persistent post-concussive symptoms (PPCS) involve an array of physical, cognitive, and behavioral symptoms lasting more than a month after mild traumatic brain injury (mTBI). 34-44% of people with mTBI or concussion present with a considerable burden of PPCS 3-6 months after injury. There is currently no standardized treatment for PPCS, nor FDA approved medication for any neuropsychiatric or neurocognitive symptoms associated with mTBI. Transcranial magnetic stimulation (TMS) shows promise as a treatment for PPCS; however, the current one-size-fits-all approach does not address the heterogeneity of symptoms. We propose utilization of resting state functional MRI (rs-fMRI) guided rTMS to target personalized brain networks burdened with PPCS.
The group in the trial
- Theta burst stimulationTreatment being tested
There will be a total of 25 theta burst sessions across 5 treatment visits (5 sessions per treatment visit), over a two-week period. Treatment will be applied to 2 brain regions of interest or parcellations: (1) Left 8AV; 2) A personalized region based on imaging and symptom profile.
Treatment: Intermittent theta burst stimulation
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Personalized Accelerated Theta Burst Transcardial Magnetic Stimulation in Mild Traumatic Brain Injury
- Record updated
- 5 November 2026